Daiichi Sankyo’s antibody–drug conjugate Datopotamab Deruxtecan secures U.S. approval, offering a new treatment for patients with previously treated …
Daiichi Sankyo’s antibody–drug conjugate Datopotamab Deruxtecan secures U.S. approval, offering a new treatment for patients with previously treated …
With a PDUFA date set for June 2025, the copper histidinate therapy may soon become the first FDA-approved …
A landmark U.S. FDA nod for Datopotamab deruxtecan (Datroway) marks a promising advance for treating metastatic HR‑positive, HER2‑negative …
A pivotal agreement between uniQure and the FDA ignites momentum for Huntington’s gene therapy, while Europe’s regulatory landscape …
In a late-2024 milestone, the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for Mesoblast’s stromal cell therapy injects …
Humacyte’s Symvess offers a novel solution for patients with severe vascular injuries, marking a significant advancement in trauma …
On December 19, the clinical research world turns its attention to psychedelic medicine, with new data, global trial …
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, …
With generative AI powering personalized insights, Dexcom’s new Stelo CGM enters the market as the first FDA-cleared over-the-counter …
With its first-in-class mechanism and monthly dosing, Depemokimab sets a new benchmark in biologic treatment for high-burden asthma …
Already a subscriber? Log in